These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23076348)

  • 1. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes.
    Morgan CL; Poole CD; Evans M; Barnett AH; Jenkins-Jones S; Currie CJ
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4605-12. PubMed ID: 23076348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
    Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
    Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
    Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.
    Currie CJ; Poole CD; Evans M; Peters JR; Morgan CL
    J Clin Endocrinol Metab; 2013 Feb; 98(2):668-77. PubMed ID: 23372169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
    Yu OH; Yin H; Azoulay L
    Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients.
    Grimes RT; Bennett K; Tilson L; Usher C; Smith SM; Henman MC
    Br J Clin Pharmacol; 2015 Jun; 79(6):1000-9. PubMed ID: 25521800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
    Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
    Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression through diabetes therapies among new elderly users of metformin: a population-based study.
    Gomes T; Juurlink DN; Shah BR; Hellings CR; Paterson JM; Mamdani MM
    Diabet Med; 2013 Feb; 30(2):e51-5. PubMed ID: 23075391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
    Currie CJ; Poole CD; Gale EA
    Diabetologia; 2009 Sep; 52(9):1766-77. PubMed ID: 19572116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes.
    Desai U; Kirson NY; Kim J; Khunti K; King S; Trieschman E; Hellstern M; Hunt PR; Mukherjee J
    Diabetes Care; 2018 Oct; 41(10):2096-2104. PubMed ID: 30131396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
    Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
    BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
    Filion KB; Douros A; Azoulay L; Yin H; Yu OH; Suissa S
    Br J Clin Pharmacol; 2019 Oct; 85(10):2378-2389. PubMed ID: 31276600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.
    Kahler KH; Rajan M; Rhoads GG; Safford MM; Demissie K; Lu SE; Pogach LM
    Diabetes Care; 2007 Jul; 30(7):1689-93. PubMed ID: 17440170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
    Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
    Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
    Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
    Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.